The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - Selecta (SELB) announced that it would report updated patient data from the ongoing Phase 2 trial of its lead product candidate, SEL-212, at the American College … Continue Reading
Read nowInsights - Fennec (FENC) presented the full data from SIOPEL 6, a Phase 3 study in cisplatin induced hearing loss in children with Standard Risk Hepatoblastoma (SR-HB). The study … Continue Reading
Read nowInsights - Short-sell Tyme Technologies (NASDAQ: TYME) at ~$6 a share Cover (buy-back) this short at <$3 a share by year-end We are short Tyme Technologies (“Tyme”), a $500m+ … Continue Reading
Read nowInsights - Zogenix (ZGNX) will be releasing data from its pivotal Phase 3 program of ‘ZX008’ intended for the treatment of Dravet Syndrome (DS), a form of … Continue Reading
Read nowInsights - We have outlined our reasoning behind certain position changes in our open/closed positions, which can be found on PropThink’s Recent Research page. Bluebird Fairly Valued … Continue Reading
PremiumInsights - Fennec Pharmaceuticals (FENC:NASDAQ) (FRX.TO:TSX) released the results of its long anticipated Phase 3 study. Interim data showed Fennec’s drug, sodium thiosulfate (“STS”) significantly reduces chemotherapy … Continue Reading
Read nowResearch - Paratek Pharmaceuticals (PRTK) released their top-line, OASIS-2 results after the bell yesterday, comparing oral omadacycline to linezolid in ABSSSI infections. Omadacycline achieved all primary and … Continue Reading
Premium
